30 closest matches · ranked by relevance
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter
Renal Impairment
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 268; 370; 396; 615 nanogram*hour/milliliter (ng*hr/mL)
Renal Impairment
Primary: Dose-Normalized Maximum Concentration of Plerixafor (Cmax) — 0.0452; 0.0388; 0.0490; 0.0475 ng/mL/ug
Impaired Renal Function
Primary: Pharmacokinetic Parameters- Plasma AUC0-24 — 16877.94; 32787.41; 64895.29; 15506.68 ng*h/mL
Renal Insufficiency
Primary: Area Under the Curve From Time Zero to 48 Hours[AUC (0 - 48)] — 1294; 1399; 2024; 2860 Nanogram*hour/milliliter (ng*h/mL)
Renal Function Impairment in Healthy Volunteers
Primary: Renal Plasma Flow — 541; 663 mL/min — p=< 0.0001
Renal Impairment · Renal Insufficiency · Kidney Disease
Primary: AUC — 102.0; 168.9; 107.4; 188.5 h*ng/mL
Pharmacokinetics · Renal Impaired · Healthy Volunteer
Primary: Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5) — 0.5; 0.5; 0.5; 0.5 hour
Renal Insufficiency
Primary: The Steady State Area Under the Drug Concentration Time Curve From 0 to 12 Hours Post Dose AUC(0-12). — 157.8; 276.5; 415.3 hour*nanogram/milliliter
Pneumonia
Primary: Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose — 17700; 22070; 28940; 10340 nanogram per milliliter (ng/mL)
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
Renal Insufficiency · Healthy
Primary: Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24) — 3.97; 7.88…
Heart Failure
Primary: AMG 986 Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast) — 80,000; 64,500…
HIV
Primary: Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total) — 138169.7; 170105.6 h*ng/mL
Insomnia
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Severe Renal Impairment Participants Versus…
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1174; 1626; 1164 nanogram per milliliter (ng/mL)
Mild and Moderate Renal Impairment
Primary: Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5) — 1; 0.5; 0.5; 0.5 hr
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2.43; 2.73; 3.69; 2.53 ng/mL
Renal Impairment
Primary: Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf) — 104; 141; 83.5; 244 µM*hr
Hepatitis C
Primary: AUC0-∞ — 76500; 86900; 136000; 129000 ng*h/mL
Healthy Volunteers · Chronic Kidney Disease
Primary: Effect of RBT-1 on Plasma Ferritin Levels — 592.3; 538.8; 313.7; 308.2 Percent change from baseline
Inflammatory Disease
Primary: Pharmacokinetic (PK) Parameter: AUClast of Lanraplenib Presented Based on Range of CLcr — 2317.8; 2027.4; 2076.3; 1871.6 h*ng/mL
Schizophrenia · Psychiatric Disorders
Primary: Unbound Area Under the Concentration (AUC) Time Curve Calculated to the Last Observable Concentration Brexpiprazole (AUCt,u). — 8.17; 13.3 nanograms*hours/mL (ng*h/mL)
Renal Impairment
Primary: Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757 — 3.81; 4.94; 533; 759 ng/mL
Healthy Volunteers · Renal Impairment
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Last Measurable Concentration (AUC0-last) of MK-6183 — 87.6; 114.8; 97.5; 228.0 ug*hr/mL
Chronic Kidney Disease (CKD)
Primary: Number of Patients With Reported Adverse Events Receiving Escalating Doses of LHW090 (Part 1) — 1; 0; 1; 2 Count of Participants
Chronic Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…
Hepatic Insufficiency, Renal Insufficiency
Primary: Maximum Observed Concentration (Cmax) of Copanlisib in Plasma. — 68.12; 71.09; 31.77; 49.20 μg/L
Healthy Volunteer · Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-06700841 Following Single Oral Dose Administration in Participants With Renal Impairment and in Healthy Participants…
Diabetes Mellitus, Type 2
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞) — 23.3; 24.9 µM*hr